Alzamend Neuro is trading 15.61% down now at $1.35 after investors reacted to an August 21, 2026 Form S-1 registration for Ault Lending’s resale of up to 98,388,305 common shares.
- Shares are issuable upon preferred-stock conversion, raising dilution and potential selling-pressure concerns.
- The company will not receive proceeds from the resale.
- The decline follows the August 25 close of $1.60; broader markets were largely mixed rather than sharply risk-off. No newer August 26 announcement was identified.